Tag

Ajax Therapeutics

All articles tagged with #ajax therapeutics

business1 month ago•8 min saved

Lilly bets big on Ajax asset as early data show rapid JAK2 inhibitor activity in MF

Lilly’s up-to-$2.3 billion acquisition of Ajax Therapeutics is being justified by early AJX-101 data showing AJ1-11095, a Type II JAK2 inhibitor, produced rapid spleen size reduction and symptom improvement in pretreated myelofibrosis patients, with reductions in mutant JAK2 allele burden and a generally favorable safety profile though anemia and thrombocytopenia occurred; most patients remained on therapy, and the company plans a Phase 3 in second-line MF while expanding to other MF subtypes, signaling a potential challenge to Incyte’s Jakafi dominance and underscoring Lilly’s strategy to back de-risked, validated assets.

via Fierce Biotech|

#aj1-11095 #ajax-therapeutics #business

business3 months ago•2 min saved

Lilly to Acquire Ajax for $2.3B to Push Next-Gen JAK2 Inhibitor AJ1-11095

Eli Lilly agreed to acquire Ajax Therapeutics for up to $2.3 billion to advance AJ1-11095, a first-in-class Type II JAK2 inhibitor in phase 1 for myelofibrosis. Lilly says the Type II inhibitor could yield deeper and more durable efficacy than existing Type I JAK2 inhibitors and help patients who develop resistance, based on Ajax’s preclinical data and a Schrödinger collaboration. The deal comprises upfront and milestone payments, and Lilly plans registrational trials after forthcoming proof-of-concept data in 2026, underscoring its ongoing aggressive biotech dealmaking.

via Fierce Biotech|

#aj1-11095 #ajax-therapeutics #business

business3 months ago•5 min saved

Lilly to acquire Ajax Therapeutics to advance next-gen JAK2 therapy for myeloproliferative neoplasms

Lilly has a definitive agreement to acquire Ajax Therapeutics for up to $2.3 billion in cash to accelerate AJ1-11095, a first-in-class Type II JAK2 inhibitor in Phase 1 for myeloproliferative neoplasms (myelofibrosis and polycythemia vera). AJ1-11095 is designed to bind a different JAK2 conformation for deeper, more durable efficacy and tolerability, with clinical proof-of-concept data expected later in 2026 and plans to move into registrational trials across first- and second-line settings.

via investor.lilly.com|

#aj1-11095 #ajax-therapeutics #business

business3 months ago•6 min saved

Lilly to acquire Ajax Therapeutics to push next-gen JAK2 inhibitor for MPNs

Eli Lilly will acquire Ajax Therapeutics in a deal worth up to $2.3 billion to advance AJ1-11095, a first-in-class Type II JAK2 inhibitor in Phase 1 for myeloproliferative neoplasms, including myelofibrosis and polycythemia vera. Designed for deeper, more durable efficacy than current JAK2 inhibitors, AJ1-11095 aims to enable longer therapy duration and broader use across first- and second-line settings, with proof-of-concept data anticipated later in 2026 and registrational trials planned.

via PR Newswire|

#ajax-therapeutics #business #jak2